Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 09:05 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response

Newly released preclinical data to be presented in a poster on November 8, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO)...
November 03, 2025 09:00 ET | Source: Aptose Biosciences, Inc.

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
November 03, 2025 08:00 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Listing on OTC Markets

Company’s Shares Will Continue to Trade Under Ticker CERO on the OTC Markets SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTC PINK: CERO)...
October 21, 2025 08:15 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics...
October 16, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
October 13, 2025 08:30 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML

Study’s Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval Company issues correction of recently...
September 22, 2025 09:15 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN...
September 09, 2025 08:15 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology SOUTH SAN FRANSCISCO,...
September 08, 2025 08:45 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13th annual conference highlighting original study protocol SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 ...
September 05, 2025 08:00 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company’s lead cancer immunotherapy program SOUTH SAN FRANSCISCO,...